WO2005013991A1 - ロラタジンを含有するドライシロップ - Google Patents
ロラタジンを含有するドライシロップ Download PDFInfo
- Publication number
- WO2005013991A1 WO2005013991A1 PCT/JP2004/011333 JP2004011333W WO2005013991A1 WO 2005013991 A1 WO2005013991 A1 WO 2005013991A1 JP 2004011333 W JP2004011333 W JP 2004011333W WO 2005013991 A1 WO2005013991 A1 WO 2005013991A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dry syrup
- water
- dry
- saccharide
- mouth
- Prior art date
Links
- 239000006188 syrup Substances 0.000 title claims abstract description 81
- 235000020357 syrup Nutrition 0.000 title claims abstract description 81
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 title claims abstract description 6
- 229960003088 loratadine Drugs 0.000 title claims abstract 5
- 238000002360 preparation method Methods 0.000 claims abstract description 45
- 229920002678 cellulose Polymers 0.000 claims abstract description 17
- 239000001913 cellulose Substances 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 150000001720 carbohydrates Chemical class 0.000 claims description 26
- 239000011230 binding agent Substances 0.000 claims description 25
- 239000006185 dispersion Substances 0.000 claims description 24
- 229930006000 Sucrose Natural products 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 239000005720 sucrose Substances 0.000 claims description 20
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 235000010980 cellulose Nutrition 0.000 claims description 16
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 15
- 239000002518 antifoaming agent Substances 0.000 claims description 15
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 15
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims description 8
- 229920005615 natural polymer Polymers 0.000 claims description 7
- 230000000704 physical effect Effects 0.000 claims description 6
- 239000006260 foam Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- 235000010449 maltitol Nutrition 0.000 claims description 3
- 239000000845 maltitol Substances 0.000 claims description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
- 229940035436 maltitol Drugs 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229920003124 powdered cellulose Polymers 0.000 claims description 2
- 235000019814 powdered cellulose Nutrition 0.000 claims description 2
- 150000005846 sugar alcohols Chemical class 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 239000002324 mouth wash Substances 0.000 claims 1
- 229940051866 mouthwash Drugs 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000002209 hydrophobic effect Effects 0.000 abstract description 4
- 235000000346 sugar Nutrition 0.000 abstract description 2
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical class NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000005469 granulation Methods 0.000 description 23
- 230000003179 granulation Effects 0.000 description 23
- 150000003839 salts Chemical class 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 239000000843 powder Substances 0.000 description 19
- -1 rice starch Polymers 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 11
- 235000014633 carbohydrates Nutrition 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 229940032147 starch Drugs 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 238000001125 extrusion Methods 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 5
- 229940068968 polysorbate 80 Drugs 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 238000004062 sedimentation Methods 0.000 description 5
- 229920002050 silicone resin Polymers 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000007970 homogeneous dispersion Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960002160 maltose Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000010665 pine oil Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- DIUFONOIVHRUKS-UHFFFAOYSA-N 4-(8-chloro-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridin-11-ylidene)piperidine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 DIUFONOIVHRUKS-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 101100081899 Arabidopsis thaliana OST48 gene Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920003116 HPC-SSL Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 239000010675 spruce oil Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a novel dosage form of mouth latadine, specifically, a dry syrup of mouth latadine.
- Oral latadine is an active ingredient of an allergic disease therapeutic agent (histamine HI receptor antagonist) marketed under the trade name "Claritin tablets”.
- Oral latazine is chemical name: 4- (8-chloro-5,6-dihydro-11H-benzo [5,6] cyclohepta [1,2-b] pyridine-11-ylidene) -1-piperidinecarboxylic acid It is a compound represented by ethyl ester and first disclosed in JP-A-57-35586.
- Pharmaceutical dosage forms include various forms such as tablets, powders, granules, capsules and the like.
- dry syrups which are one of the pharmaceutical dosage forms, correspond to “preparations that are dissolved or suspended at the time of use”. Dry syrup is easy to take, especially for children who dislike the drug and elderly people who have difficulty swallowing. Further, since the dry syrup is in the form of powder or granules, it has the advantages of being easily packaged and weighed, and being convenient to carry.
- Japanese Patent Application Laid-Open No. 57-35586 describes a liquid syrup preparation containing an analogous compound of mouth latadine, sucrose, sorbitol, water, etc., but does not describe a dry syrup preparation.
- WO02 / 05816 describes a study on a preparation for improving the bioavailability of oral latadine, but does not describe a dry syrup of oral latadine.
- JP 2000-508649 discloses that (a) at least one active substance, (b) at least one bulking agent such as sucrose (sucrose), (c) at least one binder such as a cellulose substance, and ( d) Orally disintegrating agents containing adjuvants such as talc are described. Specifically, a fast dissolving oral dosage form containing potassium diclofenac, mannitol and polyvinylpyrrolidone is described. However, dry syrup of mouth latadine is not described. Not. WO 01/26691 describes a rapidly disintegrating oral pharmaceutical composition comprising an active ingredient soluble in water and sucrose.
- a dry syrup preparation containing faropenemnatrium, sucrose, hydroxypropylcellulose and the like is disclosed.
- the drug is dissolved in water, and the resulting solution is colorless and transparent.
- a dry syrup of mouth latadine is not described.
- Oral latadine is a hydrophobic drug.
- a surfactant to mix the drug into water and an antifoaming agent to mix bubbles to disperse bubbles during dispersion in water.
- the present inventors tried to search for a substance that can substitute for the surfactant and the antifoaming agent because the desired dry syrup could not be obtained with a normal surfactant and an antifoaming agent.
- the present inventors have conducted intensive studies and have found that when a certain binder that is usually added when granulating a mixed powder having poor granulation properties is used instead of a surfactant and an antifoaming agent, The present inventors have found that a good dry syrup of latadine can be obtained which gives a uniform dispersion with almost no foaming even when poured into water and stirred, thereby completing the present invention.
- the present invention provides
- Dry syrup containing binder, saccharide and mouth latadine as an active ingredient which give a uniform dispersion when water is added at the time of use; preferably, the binder is cellulose or a natural high molecular compound, and Z or saccharide.
- the binder is cellulose or a natural high molecular compound, and Z or saccharide.
- Mouth latadine is combined with celluloses and Z or natural polymer compound to dry
- a dry syrup containing a binder, a saccharide and a mouth latadine as an active ingredient which gives a uniform dispersion when water is added, such as cellulose, is almost free of foam even when poured into water and stirred. Gives a homogeneous dispersion without any formation.
- the uniform dispersion obtained from the dry syrup preparation of the present invention does not exhibit bitterness. Therefore, the dry syrup preparation of the present invention is easy to take even for children who dislike the medicine and especially for the elderly who have difficulty swallowing. Furthermore, it is easy to package and weigh, and it is convenient to carry.
- the present invention provides, as a first aspect, a dry syrup containing a binder, a saccharide, and mouth latadine as an active ingredient, which gives a uniform dispersion when water is added at the time of use.
- the dry syrup preparation of the present invention becomes a uniform dispersion liquid when water is used.
- Homogeneous dispersion means a formulation with the following physical properties:
- Mouth latazine which is an active ingredient of the dry syrup preparation of the present invention, can be easily produced by a method described in JP-A-57-35586, which is well known to those skilled in the art.
- celluloses hydroxypropylcellulose, hydroxypropylmethylcellulose, methinolecellulose, canolemellose sodium, crystalline cenorellose 'power noremelose sodium, crystalline cellulose, powdered cellulose, hydroxypropylmethylcellulose lid Rate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose and hydroxyethylcellulose.
- natural polymer compounds include alginic acid and salts thereof, guar gum, tragacanth, tragacanth powder, carrageenan, acacia, acacia powder, agar, agar powder, white shellac, xanthan gum and gelatin.
- starch and its derivatives examples include wheat starch, rice starch, corn starch, potato starch, dextrin, pregelatinized starch, partially pre-alpha-starch, hydroxypropyl starch and pullulan.
- Synthetic polymer compounds include polyvinylpyrrolidone K25, polyvinylpyrrolidone ⁇ 30, polyvinylpyrrolidone ⁇ 90, aminoalkyl methacrylate copolymer ⁇ , aminoalkyl methacrylate copolymer RS, methacrylic acid copolymer L, methacrylic acid copolymer S, Examples include methacrylic acid copolymer LD, carboxybutyl polymer, polyvinylacetate-l-ethylethylaminoacetate and polyvinyl alcohol.
- the binder used in the present invention is selected from at least one kind of force exemplified above.
- hydroxypropylcellulose as a cellulose or alginate as a natural polymer compound is preferred, and hydroxypropylcellulose is particularly preferred.
- Hydroxypropyl cellulose includes those having a 2% aqueous solution viscosity of less than 3.0 mPa's at 20 ° C, those having a viscosity of 3.0-5.9 mPa's, and those having a viscosity of 6.0-lO.OmPa's. Less than 3.0 mPa ⁇ s is preferred.
- the carbohydrates contained in the dry syrup of the present invention include sugars and sugar alcohols, such as sucrose, glucose, mannitol, powdered reduced maltose starch syrup, maltitol, erythritol, sorbitol, maltose, lactose, starch and starch derivatives, mannose and sol.
- sugars and sugar alcohols such as sucrose, glucose, mannitol, powdered reduced maltose starch syrup, maltitol, erythritol, sorbitol, maltose, lactose, starch and starch derivatives, mannose and sol.
- Bose xylose, trehalose, funolectose, dextran, punorellan, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch, carboxymethyl cellulose mono-Na, inositol, dulcitol, xylitolone, arabitol, raffinol At least one selected from the group consisting of water, ratatitol, and palatinit. Of these, sucrose is preferred.
- Carbohydrates include non-saccharide natural and synthetic sweeteners such as aspartame, glycyrrhizic acid and its salts, saccharin and its salts, stevia and its salts, sucralose, and acesulfame potassium. Can be added.
- the dry syrup of the present invention may contain pharmaceutically acceptable additives other than those described above.
- Additives include lubricants, suspending agents, pH adjusters, preservatives, fragrances and the like.
- Lubricants include those referred to as fillers, adsorbents or fluidizers, and are selected from at least one kind such as hydrated silicon dioxide, light caustic anhydride, sucrose fatty acid ester, and magnesium stearate.
- Suspending agents include those referred to as dispersants, thickening (disintegrating) or disintegrating agents, for example the binders mentioned above.
- the pH adjuster includes so-called acids, bases or buffers, for example, hydrochloric acid, dilute hydrochloric acid, sulfuric acid, adipic acid and its salts, citric acid and its salts, dalconic acid and its salts, succinic acid and its Salt, ascorbic acid and its salts, glacial acetic acid and its salts, acetic acid and its salts, tartaric acid and its salts, fumaric acid and its salts, maleic acid and its salts, lactic acid and its salts, malic acid and its salts, phosphoric acid And at least one selected from salts thereof, glycine, sodium hydrogen carbonate, sodium carbonate, sodium hydroxide, magnesium hydroxide and the like.
- Preservatives include those referred to as stabilizing (stabilizing) agents, for example, benzoic acid and its salts, edetic acid and its salts, salicylic acid and its salts, dibutylhydroxytoluene, sorbic acid and its salts, sodium dehydroacetate, paraoxybenzoate At least one kind is selected from acids and salts thereof.
- Flavors include those referred to as flavoring agents, such as orange essence, orange oil, caramenole, camphor nole, keich oil, spearmint oil, strawberry essence, chocolate essence, cherry oil, spruce oil, pine oil, pine oil 'Oil, No Euphrait / I, Bitter Essence, Funo Flavor, ⁇ Ha. At least one selected from mint essence, mixed flavor, mint flavor, menthol, lemon powder, lemon oil and rose oil.
- the mixing ratio of each component contained in the dry syrup of the present invention is, for example, 0.1% for rat latazine.
- Ow / w% 01—50 w / w o / o , bond strength (J force SO. 5—20. Ow / w%, carbohydrate power 20.0 99.49 w / w% And preferably 0.1 to 10.
- Ow / w% of mouth ratatine 0.5 to 10.
- Ow / w% of binder and 50 to 99.4 w / w% of carbohydrate, and more.
- the mouth latadine is 0.5-5.
- the binder is 0.5-5.
- the carbohydrate is 80.0-99. Ow / w%, particularly preferred.
- Oral latadine is 0.5-3.0 wZw%
- binder is 0.5 1.0 wZw%
- carbohydrate is 90.0 99.0 w / w%.
- a preferred ingredient in the dry syrup of the present invention is a combination of mouth ratazine, hydroxypropylcellulose as a binder and sucrose as a carbohydrate.
- Particularly preferred is a dry syrup comprising 0.5 3. Ow / w% of mouth latadine, 0.5-1. Ow / w% of hydroxypropylcellulose, 0.25-0.75 w / w% of hydrous silicon dioxide and 90.0-98.75 wZw% of sucrose. It is.
- the dry syrup preparation of the present invention does not contain any of a surfactant and an antifoaming agent.
- the surfactant not to be contained is sucrose fatty acid ester, sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, polysorbate 80, and sodium lauryl sulfate.
- Antifoaming agents which should not preferably be included are silicone resin, silicone resin emulsion, silicone antifoaming agent, silicone oil, sucrose fatty acid ester, glycerin fatty acid ester, dimethylpolysiloxane, dimethylpolysiloxane; silicon dioxide mixture, polyoxyl stearate 40, sorbitan fatty acid ester, sorbitan trioleate, polysorbate 80.
- the particle size of the dry syrup is not particularly limited, but is generally in the range of the particle size of powders, fine granules, and granules according to the Japanese Pharmacopoeia.
- the dry syrup of the present invention is prepared by a usual method for producing powders, granules, and fine granules.
- a stirring granulation method for producing powders, granules, and fine granules.
- an extrusion granulation method for example, there are a stirring granulation method, an extrusion granulation method, a fluidized bed granulation method, a tumbling granulation method, a crushing granulation method, a spray granulation method, a crushing granulation method and the like.
- the agitation granulation method will be briefly described.
- a predetermined amount of mouth ratazine and saccharide are weighed, sieved with a sieve having an opening of 425 xm, and the powder passing through the sieve is put into a stirring granulator and mixed.
- a predetermined amount of a binder is added, and the mixture is granulated for a certain period of time. Then, it is dried with a suitable fluidized bed granulator. Then granulate with a granulator using a basket with an opening of 1038 xm.
- fine powder can be removed by a classifier using a wire mesh having a mesh size of 154 ⁇ m.
- An appropriate additive is blended with the obtained granules and mixed to obtain a desired dry syrup.
- some or all of the additives may be sieved at the same time as the initial mouth latadine or carbohydrate.
- the extrusion granulation method is the same as the stirring granulation method except that the drug substance, additives and the like are mixed and granulated by the stirring granulator, and then the extrusion granulator is used. it can.
- the extrusion granulator for example, a DGL1 type dome gran (Fuji Padal Co., Ltd., hole diameter: 0.5 mm) and a cylindrical granulator (Yamada Iron Works Co., Ltd., hole diameter: 0.53 mm) can be used.
- Fluidized bed granulation can be performed in the same manner except that a fluidized bed granulator is used instead of the stirred granulator used in the above stirred granulation method.
- a fluidized-bed granulator for example, a WSG-5 type granulation dryer (manufactured by Dai-J11 Hara Seisakusho) can be used.
- saccharide and mouth latadine as an active ingredient, and an aqueous solution of a binder that gives a uniform dispersion when water is added at the time of use are mixed, granulated, and dried.
- the present invention also provides a method for preparing a dry syrup, which is characterized in that:
- the present invention provides a dispersion comprising a binder, a saccharide, and mouth ratadine as an active ingredient, which give a uniform dispersion when water is added, and the mouth ratadine is uniformly dispersed in water.
- a dispersion comprising a binder, a saccharide, and mouth ratadine as an active ingredient, which give a uniform dispersion when water is added, and the mouth ratadine is uniformly dispersed in water.
- the dispersion of the present invention can be obtained by putting the dry syrup of the present invention into an appropriate amount of water and stirring.
- the present invention provides a method for improving the dispersibility of mouth latadine in water, comprising preparing a dry syrup by combining mouth latadine with celluloses and / or a natural polymer compound. I do. Details are the same as above.
- "improving dispersibility in water” means to prepare the mouth drug latadine, which is a hydrophobic drug, in water to a uniform dispersion as defined herein.
- a dry syrup having the following composition (wZw%) was prepared together with the comparative example preparation.
- composition (w Zw)%
- the amount is appropriately converted into a charged amount and weighed.
- Sucrose was used as a saccharide
- hydroxypropylcellulose HPC_SSL, the viscosity of a 2% aqueous solution at 20 ° C was less than 3.0 mPa's
- hydrous silicon dioxide was used as a lubricant.
- Example 1 20 g of mouth latadine and 1958 g of white sugar were weighed, sieved with a sieve having an opening of 425 xm, and the powder passed through the sieve was stirred with a stirring granulator (10-type high-speed mixer, manufactured by Fukae Patetech Co., Ltd.). Agitator: 300 ⁇ m, chopper: 2500 ⁇ m) and mixed for 1 minute. Thereafter, 120 g of an aqueous solution of 10 (w / w)% hydroxypropylcellulose was added, and the mixture was granulated for 3 minutes.
- a stirring granulator 10-type high-speed mixer, manufactured by Fukae Patetech Co., Ltd.
- Comparative Example 1 a predetermined amount of mouth latadine and sucrose were weighed, sieved with a sieve having an opening of 425 ⁇ m, and the powder passed through the sieve was produced in the same manner as in Example 1. For granulation, 120 g of purified water was used.
- the preparations of Comparative Examples 2 to 5 are produced in the same manner as in Example 1, but further contain polysorbate 80 (surfactant) or silicone resin (antifoaming agent).
- the amount is appropriately converted to the amount charged and weighed.
- Example 1 20 g of mouth latadine and 1958 g of white sugar were weighed, sieved with a sieve having an opening of 425 xm, and the powder passed through the sieve was stirred with a stirring granulator (10-type high-speed mixer, manufactured by Fukae Patetech Co., Ltd.). Agitator: 300 ⁇ m, chopper: 2500 ⁇ m) and mixed for 1 minute. Thereafter, 120 g of an aqueous solution of 10 (w / w)% hydroxypropylcellulose was added, and the mixture was granulated for 3 minutes.
- a stirring granulator 10-type high-speed mixer, manufactured by Fukae Patetech Co., Ltd.
- Comparative Example 2-5 is produced in the same manner as in Example 1, except that it further contains polysorbate 80 (a surfactant) or a silicone resin (an antifoaming agent).
- the amount is appropriately converted to the amount charged and weighed.
- Example 1 50 g of mouth latadine and 4895 g of white sugar were weighed out and sieved with a sieve having an aperture of 425 xm. The powder passed through the sieve was put into a fluidized bed granulator (WSG-5 type granulator / dryer, manufactured by Okawara Seisakusho) and mixed for 5 minutes. Thereafter, 1500 g of an aqueous solution of 2 (w / w)% t-doxypropylcellulose was sprayed (spray speed: 30 g / min, spray pressure: 0.15 MPa). Thereafter, drying was performed until the product temperature reached 45 ° C.
- WSG-5 type granulator / dryer manufactured by Okawara Seisakusho
- Comparative Example 1 a predetermined amount of ratatazine and sucrose was weighed, sieved with a sieve having an opening of 425 ⁇ m, and the powder passed through the sieve was produced in the same manner as in Example 1. 1500 g of purified water was used as the spray liquid during granulation.
- the preparations of Comparative Examples 2-5 are prepared in the same manner as in Example 1, but further include polysorbate 80 (surfactant) or silicone resin (antifoaming agent).
- the centrifugal sedimentation tube used for evaluation of dispersibility was left at room temperature for one day. After that, it was judged by the same evaluation method as the above-mentioned dispersibility.
- the lid of the centrifugal sedimentation tube was removed and visually observed from above. The presence or absence of suspended matter was judged as X if there was no suspended matter within 1 minute, and X if there was.
- the foam was reduced within 1 minute, and it was judged as X if the water surface was visible and X if it was not.
- the bubbles even if bubbles are generated at a height of about 1 cm immediately after shaking, the bubbles almost disappear within one minute thereafter. However, the bubbles do not completely disappear, and there is the power that small bubbles remain. Therefore, in this specification, "the bubbles decrease within one minute” means that the water surface is visible within one minute, including the case where minute bubbles remain on the water surface, And if all the bubbles disappear, it is better.
- Comparative Example 1 is different from the preparation of the present invention in that hydroxypropylcellulose is not contained, and the preparation of Comparative Example 2_5 further contains a surfactant and an antifoaming agent.
- a dry syrup containing no surfactant and no defoaming agent and using hydroxypropinolecellulose alone improved uniform dispersibility in water.
- the dry syrup of the present invention which gives a uniform dispersion and does not have a bitter taste, is easy to take and easy to take and carry quickly for children who dislike the medicine and for the elderly who have difficulty swallowing. Therefore, it is useful as a pharmaceutical.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/566,215 US20080064713A1 (en) | 2003-08-08 | 2004-08-06 | Dry Syrup Containing Loratadine |
BRPI0413428-1A BRPI0413428A (pt) | 2003-08-08 | 2004-08-06 | xarope seco contendo laratadina |
CA002533182A CA2533182A1 (en) | 2003-08-08 | 2004-08-06 | Dry syrup containing loratadine |
EP04771333A EP1652524A4 (en) | 2003-08-08 | 2004-08-06 | DRY SYRUP CONTAINING LORATADINE |
MXPA06001481A MXPA06001481A (es) | 2003-08-08 | 2004-08-06 | Jarabe en seco que contiene loratadina. |
US12/575,328 US20100022577A1 (en) | 2003-08-08 | 2009-10-07 | Dry syrup containing loratadine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003290052A JP3881640B2 (ja) | 2003-08-08 | 2003-08-08 | ロラタジンを含むドライシロップ剤 |
JP2003-290052 | 2003-08-08 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/575,328 Continuation US20100022577A1 (en) | 2003-08-08 | 2009-10-07 | Dry syrup containing loratadine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005013991A1 true WO2005013991A1 (ja) | 2005-02-17 |
Family
ID=34131573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/011333 WO2005013991A1 (ja) | 2003-08-08 | 2004-08-06 | ロラタジンを含有するドライシロップ |
Country Status (7)
Country | Link |
---|---|
US (2) | US20080064713A1 (ja) |
EP (1) | EP1652524A4 (ja) |
JP (1) | JP3881640B2 (ja) |
BR (1) | BRPI0413428A (ja) |
CA (1) | CA2533182A1 (ja) |
MX (1) | MXPA06001481A (ja) |
WO (1) | WO2005013991A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005270820B2 (en) * | 2004-08-08 | 2011-01-20 | Eliahu Khayat | Pharmaceutical compositions for alleviating excess levels of sugar in diabetic patients |
JP2007098390A (ja) * | 2005-09-12 | 2007-04-19 | Sanei Gen Ffi Inc | 消泡剤 |
JP5202856B2 (ja) * | 2006-03-06 | 2013-06-05 | 富山化学工業株式会社 | トシル酸トスフロキサシンを含有する粒状固形製剤 |
CN1820744B (zh) | 2006-04-04 | 2011-01-26 | 中国人民解放军军事医学科学院毒物药物研究所 | 磷酸奥司他韦颗粒剂及其制备方法 |
JP2009542665A (ja) * | 2006-06-29 | 2009-12-03 | シェーリング コーポレイション | 糖を含まない保存に安定な抗ヒスタミンシロップ |
WO2008098586A1 (en) | 2007-02-13 | 2008-08-21 | Dafra Pharma N.V. | Pharmaceutical carrier composition and pharmaceutical composition |
US9034618B2 (en) * | 2009-03-09 | 2015-05-19 | Ineos Bio Sa | Method for sustaining microorganism culture in syngas fermentation process in decreased concentration or absence of various substrates |
JP2010013357A (ja) * | 2008-07-01 | 2010-01-21 | Takada Seiyaku Kk | 高含量l−カルボシステインドライシロップ剤 |
TWI471146B (zh) | 2009-12-02 | 2015-02-01 | Aptalis Pharma Ltd | 菲索特芬那定(fexofenadine)微膠囊及包含其之組合物 |
KR20120087723A (ko) * | 2011-01-28 | 2012-08-07 | 제이더블유중외제약 주식회사 | 건조 시럽 조성물 |
JO3464B1 (ar) | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
MX2016014405A (es) * | 2014-05-05 | 2017-01-20 | Boehringer Ingelheim Int | Granulado de disolucion rapida. |
US10463656B2 (en) | 2017-01-05 | 2019-11-05 | Iowa State University Research Foundation, Inc. | Methods and compositions for prevention of feedlot bovine respiratory disease |
TWI826474B (zh) | 2018-06-27 | 2023-12-21 | 日商第一三共股份有限公司 | 包含二胺衍生物之顆粒劑、以及其用途及製造方法 |
JP2022502237A (ja) * | 2018-09-28 | 2022-01-11 | ダウ グローバル テクノロジーズ エルエルシー | ヒドロキシエチルセルロース誘導体泡制御剤および食材の加工方法 |
KR102193429B1 (ko) | 2018-10-26 | 2020-12-21 | 서울대학교병원 | 스마트 펜라이트 및 이를 이용한 동공 반사 분석 시스템 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5735586A (en) * | 1980-06-19 | 1982-02-26 | Schering Corp | Novel antihistamic |
JPH06157312A (ja) * | 1992-11-12 | 1994-06-03 | Shionogi & Co Ltd | 苦味改善テルフェナジンドライシロップ顆粒剤 |
JPH09208495A (ja) * | 1996-01-26 | 1997-08-12 | Kyorin Pharmaceut Co Ltd | 薬物の苦味を低減した粒状製剤及びその製造方法 |
JPH1129463A (ja) * | 1997-05-14 | 1999-02-02 | Senju Pharmaceut Co Ltd | 再分散性の良い水性懸濁液剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2042421B1 (es) * | 1992-05-22 | 1994-08-01 | Uriach & Cia Sa J | Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina. |
US5455049A (en) * | 1995-01-04 | 1995-10-03 | Ascent Pharmaceuticals, Inc. | Terfenadine oral powder |
US5824339A (en) * | 1995-09-08 | 1998-10-20 | Takeda Chemical Industries, Ltd | Effervescent composition and its production |
US20030059471A1 (en) * | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
US6132758A (en) * | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
ES2215731T3 (es) * | 1999-10-12 | 2004-10-16 | Daiichi Suntory Pharma Co., Ltd. | Composiciones medicamentosas para uso oral. |
US7223421B2 (en) * | 2000-06-30 | 2007-05-29 | Mcneil-Ppc, Inc. | Teste masked pharmaceutical particles |
IN192160B (ja) * | 2000-07-17 | 2004-02-28 | Ranbaxy Lab | |
WO2002036077A2 (en) * | 2000-11-06 | 2002-05-10 | Andrx Pharmaceuticals, Inc. | Once a day antihistamine and decongestant formulation |
US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
CN1268337C (zh) * | 2002-12-19 | 2006-08-09 | 海南普利制药有限公司 | 地氯雷他定干混悬剂及其制备方法 |
-
2003
- 2003-08-08 JP JP2003290052A patent/JP3881640B2/ja not_active Expired - Lifetime
-
2004
- 2004-08-06 WO PCT/JP2004/011333 patent/WO2005013991A1/ja active Application Filing
- 2004-08-06 CA CA002533182A patent/CA2533182A1/en not_active Abandoned
- 2004-08-06 US US10/566,215 patent/US20080064713A1/en not_active Abandoned
- 2004-08-06 EP EP04771333A patent/EP1652524A4/en not_active Withdrawn
- 2004-08-06 MX MXPA06001481A patent/MXPA06001481A/es active IP Right Grant
- 2004-08-06 BR BRPI0413428-1A patent/BRPI0413428A/pt not_active IP Right Cessation
-
2009
- 2009-10-07 US US12/575,328 patent/US20100022577A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5735586A (en) * | 1980-06-19 | 1982-02-26 | Schering Corp | Novel antihistamic |
JPH06157312A (ja) * | 1992-11-12 | 1994-06-03 | Shionogi & Co Ltd | 苦味改善テルフェナジンドライシロップ顆粒剤 |
JPH09208495A (ja) * | 1996-01-26 | 1997-08-12 | Kyorin Pharmaceut Co Ltd | 薬物の苦味を低減した粒状製剤及びその製造方法 |
JPH1129463A (ja) * | 1997-05-14 | 1999-02-02 | Senju Pharmaceut Co Ltd | 再分散性の良い水性懸濁液剤 |
Non-Patent Citations (2)
Title |
---|
"Dai jusan kaisei nippon yakkyokukata kaisetsu sho", KABUSHIKI KAISHA HIROKAWA SHOTEN, vol. A107, 1996, XP002984984 * |
See also references of EP1652524A4 * |
Also Published As
Publication number | Publication date |
---|---|
MXPA06001481A (es) | 2006-08-23 |
JP2005060265A (ja) | 2005-03-10 |
BRPI0413428A (pt) | 2006-10-10 |
EP1652524A1 (en) | 2006-05-03 |
JP3881640B2 (ja) | 2007-02-14 |
EP1652524A4 (en) | 2012-03-28 |
CA2533182A1 (en) | 2005-02-17 |
US20100022577A1 (en) | 2010-01-28 |
US20080064713A1 (en) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100022577A1 (en) | Dry syrup containing loratadine | |
JP2021178871A (ja) | エンザルタミドの製剤 | |
TWI471146B (zh) | 菲索特芬那定(fexofenadine)微膠囊及包含其之組合物 | |
TW201036649A (en) | Tablets and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide | |
CN104650091A (zh) | 替格瑞洛的微粉化及其晶型,以及制备方法和药物应用 | |
US10596263B2 (en) | Pazopanib formulation | |
TWI826474B (zh) | 包含二胺衍生物之顆粒劑、以及其用途及製造方法 | |
JP4640821B2 (ja) | 難水溶性薬物を含むドライシロップ剤 | |
WO2006109737A1 (ja) | 苦味が低減されたプランルカスト水和物を含有する製剤 | |
JP3899522B2 (ja) | 苦味が低減されたプランルカスト水和物を含有する製剤 | |
JP2008094751A (ja) | プランルカスト水和物含有医薬組成物 | |
TW200835527A (en) | Orally disintegrating tablet and bitter taste-masked formulation comprising risperidone | |
US6515008B1 (en) | Formulation | |
JP6853828B2 (ja) | メマンチンまたはその薬学上許容される塩を含有する医薬組成物 | |
JP5132090B2 (ja) | 塩酸エピナスチンドライシロップ剤 | |
JP2010053048A (ja) | 苦味が緩和されたイルベサルタン含有医薬組成物 | |
US20190380965A1 (en) | Quick Water-Dispersible Pharmaceutical Compositions of Flucytosine | |
US20240091367A1 (en) | Orally disintegrating palatable formulations of drotaverine and method of preparation thereof | |
JP2006316051A (ja) | 苦味が低減されたプランルカスト水和物を含有する製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2533182 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 06011050 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/001481 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004771333 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10566215 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004771333 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0413428 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10566215 Country of ref document: US |